Merck Becomes One of the First CDMOs to Offer a Complete Viral Vector Offering with the Launch of the VirusExpress® 293 Adeno-Associated Virus Production Platform USA – Français Deutschland – Deutsch España – español

0
  • Reduces process development time by approximately 40%
  • Enables biopharmaceutical companies to accelerate the speed of clinical manufacturing
  • Adds to the company’s best VirusExpress® Lentiviral Production Platform

DARMSTADT, Germany, August 9, 2022 /PRNewswire/ — Merck, a leading science and technology company, has launched the Virus Express® 293 Adeno-associated virus (AAV) production platform, making it one of the first CDMOs and technology developers to offer a complete viral vector manufacturing offering including AAV, Lentiviral, CDMO, CTO and process development. This new platform enables biopharmaceutical companies to accelerate clinical manufacturing while reducing process development time and costs.

“Cell and gene therapies offer the potential for cures and can be brought to market in half the time of traditional therapies,” said Dirk Lange, Head of Life Science Services, Life Science business area at Merck. “By increasing dose yields and dramatically reducing process development time, our VirusExpress® The 293 AAV production platform will accelerate the manufacturing of these therapies, ultimately delivering lifesaving treatments to patients faster. »

The new platform is an extension of the company’s VirusExpress® offer, which can reduce process development time by up to 40%, based on Merck’s experience as a CDMO. Company VirusExpress® The lentiviral production platform has enabled customers to accelerate clinical manufacturing, achieve a titer five times higher than the leading competitor, and transition from a legacy process to a model-based solution.

VirusExpress from Merck® The platforms offer a streamlined upstream workflow for AAV and lentivirus production, making it easier to manage, adjust, and scale processes. In addition to accelerating process development, the suspension culture format allows for larger batch yields to allow for more patient doses. Additionally, suspension culture lends itself to robust and scalable manufacturing processes, while requiring less labor. Chemically defined cell culture medium eliminates safety, regulatory, and supply chain issues associated with animal and human-derived materials. Flexible licensing allows companies to manufacture vectors using Merck’s contract manufacturing capabilities and expertise with access to upstream and downstream models or using in-house or third-party development.

Merck’s Life Science business segment is a leading CDMO and has been involved in this space since the start of clinical trials for gene therapy in the 1990s. October 2021the company opened its second Carlsbad, California-, more than doubling its existing production capacity to support large-scale commercial manufacturing.

All Merck press releases are distributed via email as soon as they are available on Merck’s website. please go to www.merckgroup.com/subscribe to register online, modify your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates in life sciences, healthcare and electronics. More than 60,000 employees work every day to make a positive difference in the lives of millions of people by creating more joyful and sustainable lifestyles. From advancing gene-editing technologies, to discovering unique ways to treat the toughest diseases, to enabling device intelligence, the company is everywhere. In 2021, Merck achieved a turnover of 19.7 billion euros in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advancements. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly traded company. Merck owns the worldwide rights to the Merck name and brand. The only exceptions are United States and Canadawhere Merck’s business segments operate as MilliporeSigma in life sciences, EMD Serono in healthcare, and EMD Electronics in electronics.

Photo – https://mma.prnewswire.com/media/1874155/Merck_VirusExpress.jpg

SOURCEMerck

Share.

Comments are closed.